atomoxetine hydrochloride has been researched along with levodopa in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Jankovic, J | 1 |
Feinstein, DL; Galea, E; McGuire, S; Polak, PE; Sharp, A; Simonini, MV | 1 |
1 trial(s) available for atomoxetine hydrochloride and levodopa
Article | Year |
---|---|
Atomoxetine for freezing of gait in Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Antiparkinson Agents; Atomoxetine Hydrochloride; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Propylamines; Severity of Illness Index | 2009 |
3 other study(ies) available for atomoxetine hydrochloride and levodopa
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing CNS noradrenaline reduces EAE severity.
Topics: Adrenergic Uptake Inhibitors; Animals; Astrocytes; Atomoxetine Hydrochloride; Benserazide; Benzylamines; Brain Chemistry; Central Nervous System; Cytokines; Dopamine Agents; Encephalomyelitis, Autoimmune, Experimental; Female; Glial Fibrillary Acidic Protein; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Norepinephrine; Propylamines; T-Lymphocytes | 2010 |